Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT05222984
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Decitabine — DRUGGiven IV
- Navitoclax — BIOLOGICALGiven PO
- Venetoclax — DRUGGiven PO
Study Details
This phase Ib trial is to find the side effect and best dose of navitoclax when given together with venetoclax and decitabine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory) after previous treatment with venetoclax. Chemotherapy drugs, such as navitoclax, venetoclax, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Key Dates
- Start date
- Jul 29, 2022
- Status verified
- Apr 2026
- Primary completion
- Mar 2, 2027
- Completion
- Mar 2, 2027
Study Design
- Enrollment
- 17 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (navitoclax, venetoclax, decitabine)Patients receive venetoclax PO QD and navitoclax PO QD on days 1-35, and decitabine IV over 1 hour on days 8-12 of cycle 1. Starting on cycle 2, patients receive venetoclax PO QD and navitoclax PO QD on days 1-28, and decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Incidence of adverse events [ Time Frame: Up to 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | - |
Find similar trials in Duarte, CA
By research site
Related Studies
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California
- Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionPHASE1/PHASE2 · Recruiting · Ohio State University Comprehensive Cancer Center · Sacramento, California
- Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailurePHASE2 · Recruiting · Brian Jonas · Clovis, California
- CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid LeukemiaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California